OKYO Pharma Limited
(Incorporated and registered in Guernsey with registered number 65220)
(“OKYO” or the “Company“)
Result of General Meeting, Admission of Subscription Shares and Total Voting Rights
Result of the General Meeting
The Company is pleased to announce that at the general meeting (the “General Meeting”) held earlier today the proposed resolution set out in the notice of General Meeting dated 26 April 2019 was duly passed.
The number of votes ‘for’, ‘against’ and subject to the discretion of the chair of the General Meeting cast in relation to the resolution put before the General Meeting and the number of votes ‘withheld’ were as follows:
| # | Description | For | Against | Discretion | Total Votes | Withheld | |||
| No. of Votes | % Votes Cast | No. of Votes | % Votes Cast | No. of Votes | % Votes Cast | No. of Votes (excluding Votes Withheld) | No. of Votes | ||
| 1 | Whitewash resolution | 181,901 | 82.68 | 8,667 | 3.94 | 29,450 | 13.38 | 220,018 | 32,600 |
Notes:
– Votes ‘withheld’ are not counted in the calculation of the proportion of votes ‘for’ or ‘against’ a resolution.
– The total number of Ordinary Shares in issue as at the record time for the General Meeting was 524,108,283
Admission of Subscription Shares
Applications have been made to the Financial Conduct Authority (the “FCA”) and the London Stock Exchange plc, respectively, for the admission of the 36,363,636 subscription shares (the “Subscription Shares”) to the standard segment of the official list of the FCA and to trading on the main market of London Stock Exchange plc (“Admission“).
It is expected that Admission will become effective and that dealings in the Subscription Shares will commence at 8:00 a.m. on 22 May 2019. The Subscription Shares will, on Admission, rank pari passu with the ordinary shares of no par value each in the capital of the Company (the “Ordinary Shares”).
Total Voting Rights
Following Admission, the enlarged issued share capital will comprise 560,471,919 Ordinary Shares, with voting rights. This figure may be used by OKYO shareholders as the denominator for the calculations by which they will determine whether they are required to notify their interests in, or a change to their interest in, the Company under the FCA’s Disclosure Guidance and Transparency Rules. The Company does not hold any Ordinary Shares in treasury.
End
Enquiries:
| OKYO Pharma Limited | Willy Simon | +44 (0)20 7382 8300 |
| Stockdale Securities Limited (Broker) | Andy Crossley Antonio Bossi David Coaten | +44 (0)20 7601 6100 |
For further information, please visit the Company’s website at www.okyopharma.com.